NASDAQ$OFIX

Orthofix Medical Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Orthofix's financial performance was reported for Q4 2021, showing increased net sales and strategic advancements.

Orthofix reported a 6% increase in net sales for the fourth quarter of 2021, driven by double-digit growth in Global Spinal Implants and Orthopedics. Despite headwinds, the company delivered double-digit revenue growth and advanced strategic initiatives. The company anticipates accelerating top line growth in 2022 and beyond.

  • Net sales for the fourth quarter increased by 6% year-over-year to $125.1 million.
  • Double-digit net sales growth was achieved in both Global Spinal Implants and Orthopedics compared to the prior year period.
  • EPS was $(1.65) and adjusted EPS was $0.27 for the fourth quarter.
  • The company entered into a partnership and investment with nView medical.

Headline financials

Total Revenue

$125M

Previous: $118M+6.3%
EPS (adj)

$0.27

Previous: $0.44-38.6%
Capital Expenditures

$6.23M

Previous: $3.86M+61.3%
Free Cash Flow

$5.55M

Previous: $57.2M-90.3%
Net Income

-$32.8M

Previous: -$9.38M-249.9%
Operating Income

-$9.35M

Previous: $3.71M-352.4%
Gross Profit

$91.8M

Previous: $88.5M+3.7%
Cash & Equivalents

$87.8M

Previous: $96.3M-8.8%
Total Assets

$477M

Previous: $526M-9.4%
Stock-Based Comp

$3.96M

Previous: $3.81M+4.0%

Revenue & EPS history

Orthofix · Revenue · Quarterly

$125M

Q4 2021+6.3%vs Q4 2020
Beat estimate in 8 of 16 quarters(50%)
ActualEstimate

Revenue by segment

Orthofix · $110M total across 3 segments · Q4 2021

  • Bone Growth Therapies
    $49.6M-1.7%
  • Spinal Implants & Biologics
    $31.2M+11.9%
  • Global Limb Reconstruction
    $29.2M

Forward guidance

The Company expects net sales between $475.0 million and $490.0 million, adjusted EBITDA between $56.0 million and $61.0 million, and adjusted EPS between $0.58 and $0.73 for the year ended December 31, 2022.

Tailwinds

  • Net sales are expected to increase by 2% to 5% on a reported basis.
  • Net sales are expected to increase by 3% to 6% on a constant currency basis.

Headwinds

  • Adjusted EBITDA is expected to decrease by 9% to 0%.
  • Adjusted EPS is expected to decrease by 33% to 15%.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.9%

Avg return

Earnings day

-2.6%

Avg return

5 days after

-3.4%

Avg return

30 days after

48%

31 / 65 earnings

Positive

+20.3%

Q2 2014

Best reaction

-18.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.8%-2.8%-13.8%
Q4 2025-7.0%-0.4%-13.2%
Q3 2025-7.4%-6.8%-1.0%
Q1 2025-10.8%-10.6%-20.9%
Q4 2024-3.5%-4.2%-11.0%
Q3 2024+5.5%+4.6%+1.2%
Q2 2024+13.8%+10.8%+16.7%
Q1 2024+10.7%+8.8%+0.6%
Q4 2023+8.1%+7.1%+8.6%
Q3 2023-12.5%-20.2%-3.2%
Q2 2023+9.9%+7.6%+1.3%
Q1 2023+1.0%-2.3%+6.7%
Q4 2022-7.7%-13.2%-15.5%
Q3 2022-2.2%+4.1%+30.5%
Q2 2022-6.6%-8.8%-20.9%
Q1 2022-10.5%-14.3%-11.6%
Q4 2021+4.0%+3.5%+0.4%
Q3 2021-5.9%-10.9%-18.6%
Q2 2021+8.9%+4.1%+12.4%
Q1 2021+0.5%-2.0%-8.7%
Q4 2020+0.6%-0.5%-7.3%
Q3 2020+5.2%+13.6%+10.8%
Q2 2020+4.5%+4.6%-13.4%
Q1 2020-1.9%-6.9%+3.9%
Q4 2019-18.5%-21.5%-40.9%
Q3 2019-16.8%-17.0%-9.6%
Q2 2019+0.1%+2.6%-5.5%
Q1 2019-2.6%-0.3%-10.9%
Q4 2018-8.5%-10.0%-14.8%
Q3 2018+7.4%+8.8%+4.1%
Q2 2018-15.1%-11.9%-12.1%
Q1 2018-13.4%-14.6%-10.5%
Q4 2017+6.4%+4.6%+8.4%
Q3 2017+8.8%+5.1%+9.6%
Q2 2017+9.9%+6.8%+12.3%
Q1 2017+1.4%+3.8%+8.2%
Q4 2016-6.1%-4.8%+2.6%
Q3 2016-3.8%-6.8%-1.5%
Q2 2016-10.4%-10.5%-4.8%
Q1 2016+0.4%
Q4 2015+2.8%
Q3 2015+14.4%
Q2 2015+13.8%
Q1 2015+0.4%
Q4 2014-10.8%
Q3 2014+20.3%
Q2 2014+20.3%
Q1 2014+4.2%
Q4 2013+14.1%
Q3 2013+1.1%
Q2 2013-0.8%
Q1 2013-16.4%
Q4 2012-4.9%
Q3 2012-2.8%
Q2 2012+4.5%
Q1 2011-0.7%
Q1 2012+1.0%
Q1 2010-4.8%
Q4 2011-4.8%
Q4 2009-4.8%
Q3 2010-7.4%
Q3 2011-7.4%
Q4 2010-9.5%
Q2 2010-9.5%
Q2 2011-9.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro